Biologics in Systemic Sclerosis

Title:Biologics in Systemic Sclerosis

Volume: 15 Issue: 6

Author(s): Jingxiu Xuan, Long Shen, Chongjie Zhang and Julian L. Ambrus Jr.

Affiliation:

Keywords: Antibodies, biologics, fibrosis, pathogenesis, systemic sclerosis.

Abstract: Systemic sclerosis (scleroderma) is a heterogeneous autoimmune disorder characterized by collagen overproduction that leads to cutaneous and internal organs sclerosis and pulmonary arterial hypertension. SSc has high morbidity and mortality. SSc pathogenesis is uncertain. At present most therapies of SSc are symptomatic. Effective therapeutic approaches are lacking. Accompanying a growing understanding of SSc pathogenesis, various key mediators are being evaluated as the therapeutic targets. This review described the effects of these key mediators in SSc.

Cite this article as:

Xuan Jingxiu, Shen Long, Zhang Chongjie and Jr. L. Ambrus Julian, Biologics in Systemic Sclerosis, Current Pharmaceutical Biotechnology 2014; 15(6) . https://dx.doi.org/10.2174/138920101506140910150749